Advaxis to Present at the 2012 Southern California Investment Forum & the OneMedForum NY 2012 Conference

Advaxis to Present at the 2012 Southern California Investment Forum & the OneMedForum NY 2012 Conference

Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business DevelopmentorRusso PartnersMatt Middleman, M.D.David SchullT: 212-845-4272T: 212-845-4271

., a leader in developing the next generation of immunotherapies for cancer and infectious diseases,announced that Thomas Moore, Chairman & CEO of Advaxis, will present at the 2012 Southern California Investment Forum that will take place July 10&11, 2012 in both San Francisco, California and Las Vegas, Nevada.

Thomas Moore, Chairman & CEO of Advaxis, will also present at the OneMedForum NY 2012 Conference on July 12 at 10.40am EST at the Metropolitan Club. The presentation will be webcast at .

The Southern California Investment Forum (SCIF), is an expansion of the ongoing road-show and conference activities of WallStreet Research™, a thirty year old independent research firm, which has been running conferences, road shows and investor gatherings nationally for over twenty years. For more information please visit: .

OneMedForum New York is the definitive conference in North America for fast-growing and emerging healthcare and life science companies. Now in its third year, the bi-annual forum invites companies with disruptive technology to connect with high-net worth strategic and financial investors in the space. The forum will introduce emerging companies to a privileged network of investors through unique meeting platforms, workshops and more. Additional information can be found at: .

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the .

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the , , the , the , the , the , and others. For more information please visit: | |

.

Suggested Articles

Former Ipsen and Novartis exec Harout Semerjian has been tapped as the latest chief executive of troubled Immunomedics.

A COVID-19 vaccine developed by a Mass General spinoff is among the candidates emerging from partnerships between tech developers and bio researchers.

Vir and GlaxoSmithKline will pool their resources to develop vaccines and treatments for coronaviruses, starting with two antibodies against COVID-19.